tradingkey.logo

ACIP Recommends Merck’s Enflonsia for RSV Prevention in Infants Under 8 Months

ReutersJun 26, 2025 6:39 PM

- Merck & Co Inc MRK.N:

  • ACIP RECOMMENDS USE OF MERCK’S ENFLONSIA™ (CLESROVIMAB-CFOR) FOR PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) LOWER RESPIRATORY TRACT DISEASE IN INFANTS YOUNGER THAN 8 MONTHS OF AGE BORN DURING OR ENTERING THEIR FIRST RSV SEASON

  • MERCK & CO INC - ENFLONSIA ORDERING BEGINS IN JULY, SHIPMENTS BEFORE 2025-2026 RSV SEASON

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI